Overview
The Clinical Stem Cell Center of Drum Tower Hospital, established in 2015, was in the 1st list of the 30 authorized clinical research hospitals by theNational Health and Family Planning Commission for conducting clinical trials with cell treatment products. Currently, Stem Cell Research and Preparation Center of Nanjing, Platform of Stem Cell Industry Transformation Group, and Nanjing Medical High-Tech Public Service Platform wereestablished basing on the foundation of clinical stem cell center. There is a fully functional GMP workshop with all modern equipment including GMP clinical stem cell preparation room, stem cell producing room, stem cell quality test room, and stem cell frozen storage room. This center passed the acceptance of the engineering and purification facilitates as well as environment monitoring. All of these met the requirements involved in the Chinese Pharmaceutical Industry Clean Room Design Code(GMP), which ensures that it can be used to prepare qualified stem cell products.
Conditions Treated
Providing some special services such as stem cell preparation, storage, scientific study, and clinical application.
Leadership
Dr. Bin Wang, who mainly engaged in stem cell and regenerative medical research, is the academic leader and researcher. He received his Ph.D. degree in developmental biology from Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences in 2008. He also did his postdoctoral training at Cornell University from 2008-2009 and Duke University from 2009-2013. There are 14 staff members in the clinical stem cell center, including 8 with master’s or higher degree and 4 doctors with oversea education experience. Among them, there is one with senior professional title, one with deputy senior professional title, and two clinical examiners.
Research&Achievement
We have hosted or participated in 18 research projects belonging to Ministry of Science and Technology, National Natural Science Foundation, Jiangsu Province or Nanjing. Our members published 24 SCI papers as the first author or corresponding authors (within 5 years), and the cumulative impact factor of these papers was more than 100. We have not only achieved a lot in basic research and clinical application of stem cells but also authorized and applied for 10 national invention patents. The umbilical cord mesenchymal stem cells (UMSC) products, which acquired the third-party authoritative compound inspection report of China Food and Drug Testing institute, have been used as therapeutic seed cells to perform multiple clinical studies and been recorded in the national clinical trial projects. A mature stem cell quality control system and platform has been established, which can test the quality of various stem cells and immune cells.
Education & Training
There are 7 joint-training graduate students from Nanjing University, Nanjing Medical University, and Southeast University.